Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...

A new study found the drug kept head and neck cancers at bay for five years compared to 30 months with standard care ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

A grandad with advanced lung cancer, which often leaves patients dead within four months has become free of the disease after ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...